The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
复制标题
DOI：
10.1111/j.1365-2141.2010.08099.x
复制
发表时间：
2010-05-01
影响因子：
6.5
通讯作者：
Hillmen, Peter
中科院分区：
文献类型：
--
作者：
Kelly, Richard;Arnold, Louise;Hillmen, Peter
在阵发性夜间血红蛋白尿（PNH）中，妊娠与母体和胎儿并发症的增加相关，以至于这种情况被认为是PNH的相对禁忌症。Eculizumab彻底改变了PNH的治疗。我们评估了迄今为止它在妊娠中的应用。我们报告了7例在妊娠不同阶段暴露于eculizumab的患者，包括前两例从受孕到分娩接受该药物的患者。分娩时采集的脐带血样本没有补体阻断的证据。在这种情况下使用Eculizumab似乎是安全的，并且可能预防许多通常观察到的并发症。
P>In Paroxysmal nocturnal haemoglobinuria (PNH), pregnancy is associated with increased maternal and foetal complications to such an extent that the condition has been considered relatively contra-indicated in PNH. Eculizumab has revolutionized the treatment of PNH. We evaluate its use in pregnancy to date. We report on seven patients exposed to eculizumab at different stages of pregnancy including the first two patients to receive the drug from conception to delivery. There was no evidence of complement blockade from cord blood samples taken at delivery. Eculizumab appears safe to use in this setting and is likely to prevent many of the complications usually observed.